Publication Author: Urban_Nicole

• Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers.

  Sato AH, Anderson GL, Urban N, McIntosh MW. Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. Cancer Biomark. 2006;2(3-4):151-62.

  rakerr2

  September 21, 2006

• Current and future developments in screening for ovarian cancer.

  Urban N, Drescher C. Current and future developments in screening for ovarian cancer. Womens Health (Lond Engl). 2006 Sep;2(5):733-42. doi: 10.2217/17455057.2.5.733.

  rakerr2

  September 1, 2006

• Bead-based ELISA for validation of ovarian cancer early detection markers.

  Scholler N, Crawford M, Sato A, Drescher CW, O’Briant KC, Kiviat N, Anderson GL, Urban N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

  rakerr2

  April 1, 2006

• Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

  Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteo

  rakerr2

  March 1, 2006

• Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

  Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006 Feb 10;24(5):762-8. Epub 2006 Jan 3.

  rakerr2

  February 10, 2006

• Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer.

  Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005 Feb;28(1):17-20.

  rakerr2

  February 1, 2005

• Assertiveness with physicians is related to women’s perceived roles in the medical encounter.

  Andersen MR, Abullarade J, Urban N. Assertiveness with physicians is related to women’s perceived roles in the medical encounter. Women Health. 2005;42(2):15-33.

  rakerr2

  January 1, 2005

• Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

  McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004 Oct;95(1):9-15.

  rakerr2

  October 1, 2004

• Examining the cost-effectiveness of cancer screening promotion.

  Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. Cancer. 2004 Sep 1;101(5 Suppl):1229-38. Review.

  rakerr2

  September 1, 2004

• Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you find.

  Andersen MR, Nelson J, Peacock S, Giedzinska A, Dresher C, Bowen D, Urban N. Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet A. 2004 Aug 30;129A(2):130-5.

  rakerr2

  August 30, 2004